24 Results for "

NHL

" in MedChemExpress (MCE) Product Catalog:
Products (24)

24 Results for "NHL" in MCE Product Catalog:

2
2 Cited Publications
Cat. No.: HY-P99931
CAS No.: 2134641-34-0
Synonyms: GEN3013
Target:  

CD3 CD20

Research Areas:  

Cancer

Epcoritamab (GEN3013) is an bispecific IgG1 antibody redirecting T-cells toward CD3×CD20 + tumor cells. Epcoritamab induces potent T-cell-mediated cytotoxicity towards B-cell NHL cell lines .
loading...
    loading...
2
2 Cited Publications
Cat. No.: HY-P99711
CAS No.: 1875032-68-0
Synonyms: RB4v1.2

Target:  

CD19 ADC Antibodies

Research Areas:  

Cancer

Loncastuximab (RB4v1.2) is an anti-CD19 monoclonal antibody. Loncastuximab has antitumor activity and can be used in the research of Non-Hodgkin Lymphoma (NHL) and Diffuse Large B-cell Lymphoma (DLBCL). Loncastuximab is capable of synthesizing the ADC molecule Loncastuximab tesirine (HY-P99349) .
loading...
    loading...
1
1 Cited Publications
Cat. No.: HY-P99055
CAS No.: 934823-49-1
Synonyms: BMS-663513
Target:  

TNF Receptor

Research Areas:  

Inflammation/Immunology Cancer

Urelumab, a fully human, non-ligand binding, CD137 agonist IgG4 monoclonal antibody, enhances T-cell and natural killer-cell antitumor activity, and may enhance cytotoxic activity of Rituximab (HY-P9913). Urelumab can be used for the research of diffuse large B-cell lymphoma (DLBCL), follicular lymphoma (FL), and other types of non-Hodgkin lymphoma (NHL) .
loading...
    loading...
1
1 Cited Publications
Cat. No.: HY-P99024
CAS No.: 2229047-91-8
Synonyms: RO7082859; RG-6026

Target:  

CD20 CD3

Research Areas:  

Inflammation/Immunology Cancer

Glofitamab (RO7082859) is a T-cell-engaging bispecific antibody possessing a novel 2:1 structure with bivalency for CD20 on B cells and monovalency for CD3 on T cells. Glofitamab leads to T-cell activation, proliferation, and tumor cell killing upon binding to CD20 on malignant cells. Glofitamab induces durable complete remissions in relapsed or refractory B-Cell non-Hodgkin lymphoma (B-NHL) .
loading...
    loading...
1
1 Cited Publications
Cat. No.: HY-P99033
CAS No.: 1905409-39-3
Synonyms: BTCT-4465A; RG-7828; RO7030816
Target:  

CD20 CD3

Research Areas:  

Cancer

Mosunetuzumab (BTCT-4465A) is a full-length, fully humanized immunoglobulin G1 (IgG1) T-cell-dependent bispecific (TDB) antibody targeting CD20 (B cells) and CD3 (T cells). Mosunetuzumab redirects T cells to engage and eliminate malignant B cells and can be used for the research of relapsed or refractory (R/R) B-cell non-Hodgkin lymphomas (B-NHLs). The Fc region of Mosunetuzumab incorporates a "knob-into-hole" structural modification and an N297G point mutation to achieve heterodimerization and eliminate Fc glycosylation, thereby effectively silencing antibody effector functions .
loading...
    loading...
1
1 Cited Publications
Cat. No.: HY-P990855
Anti-CD8α Antibody (OKT-8) is an anti-human CD8α IgG2a monoclonal antibody. Anti-CD8α Antibody (OKT-8) can reduce the secretion of IFNγ. Anti-CD8α Antibody (OKT-8) can deplete CD8 + T cells. Anti-CD8α Antibody (OKT-8) can be used for researches on inflammation conditions and cancer such as B non-Hodgkin lymphomas (B-NHLs). The recommend isotype control of Anti-CD8α Antibody (OKT-8): Mouse IgG2a kappa, Isotype Control (HY-P99978) .
loading...
    loading...
1
1 Cited Publications
Cat. No.: HY-P99272
CAS No.: 1375830-34-4
Synonyms: BMS 936564; MDX 1338; Anti-Human CXCR4 Recombinant Antibody

Target:  

CXCR

Research Areas:  

Cancer

Ulocuplumab (Anti-Human CXCR4 Recombinant Antibody/BMS-936564/MDX1338) is a fully human IgG4 anti-CXCR4 antibody. Ulocuplumab induces apoptosis and inhibits CXCL12 mediated CXCR4 activation-migration of chronic lymphocytic leukemia (CLL). Ulocuplumab exhibits antitumor activity in established tumors including acute myeloid leukemia (AML), non-Hodgkin lymphoma (NHL), and multiple myeloma xenograft models .
loading...
    loading...
Cat. No.: HY-P99289
CAS No.: 205923-57-5
Synonyms: Antibody hLL 2; AMG-412

Target:  

CD22

Research Areas:  

Inflammation/Immunology Cancer

Epratuzumab (Antibody hLL 2) is an anti-CD22 IgG1 monoclonal antibody. Epratuzumab is also a tumor-imaging agent and an immunomodulatory agent. Epratuzumab can induce CD22 phosphorylation. Epratuzumab has been used to research non-Hodgkin’s lymphomas (NHL) and certain autoimmune diseases .
loading...
    loading...
Cat. No.: HY-P99224
CAS No.: 728917-18-8
Synonyms: IMMU-106; hA20

Target:  

Integrin

Research Areas:  

Cancer

Veltuzumab (IMMU-106) is a humanized anti-CD20 monoclonal antibody. Veltuzumab has low EC50 value of 0.08-0.09 μg/mL in the Daudi cell line. Veltuzumab can be used for the research of cancer including non-Hodgkin lymphoma (NHL) .
loading...
    loading...
Cat. No.: HY-160167
CAS No.: 2662512-15-2
Synonyms: DZD8586
Target:  

Src Btk

Research Areas:  

Inflammation/Immunology Cancer

Birelentinib (DZD8586) is an orally effective, selective, non-covalent inhibitor targeting LYN tyrosine kinase and BTK tyrosine kinase, capable of penetrating the blood-brain barrier. Birelentinib exhibits concentration-dependent antiproliferative effects in RI-1 cells and diffuse large B-cell lymphoma (DLBCL) cell lines carrying BTK resistance mutations (such as C481X, V416L, etc.). Birelentinib blocks both BTK-dependent and independent signaling of the B-cell receptor (BCR), thereby inhibiting tumor cell proliferation and inducing cell death. Birelentinib can be used in research to overcome resistance to existing covalent and non-covalent BTK inhibitors in B-cell non-Hodgkin lymphoma (B-NHL) .
loading...
    loading...
Cat. No.: HY-P99656
CAS No.: 1906205-76-2
Synonyms: MCDS0593A

Target:  

ADC Antibodies

Research Areas:  

Cancer

Iladatuzumab (MCDS0593A) is a humanized IgG1 anti-human CD79B monoclonal antibody. Iladatuzumab can be used to synthesize antibody-drug conjugates (ADC) Iladatuzumab vedotin (DCDS0780A; HY-P99657), which has the potential for B-cell non-Hodgkin lymphoma (B-NHL) research .
loading...
    loading...
Cat. No.: HY-12908
CAS No.: 1235032-75-3
Purity:  98.86%
Target:  

Bcl-2 Family Apoptosis

Research Areas:  

Cancer

Bcl-xL antagonist 2 is a potent, selective, and orally active antagonist of BCL-XL with an IC50 and Ki of 0.091 μM and 65 nM, respectively. Bcl-xL antagonist 2 promotes the apoptosis of cancer cells. Bcl-xL antagonist 2 has the potential for the research of the chronic lymphocytic leukemia (CLL) and non-Hodgkin’s lymphoma (NHL) .
loading...
    loading...
Cat. No.: HY-P991085

Target:  

PD-1/PD-L1

Research Areas:  

Cancer

HX009 is a bispecific antibody targeting PD1 and CD47, but with weakened CD47 binding. HX009 blocks the functional of PD1/CD47. HX009 can be used for the study of non-Hodgkin’s lymphoma (NHL) .
loading...
    loading...
Cat. No.: HY-P99851
CAS No.: 145832-33-3
Synonyms: SPECIFID

Target:  

Inhibitory Antibodies

Research Areas:  

Cancer

Detumomab is a mouse monoclonal antibody targeting human B-cell lymphoma. Detumomab can be used in the research of cancers such as non-Hodgkin's lymphoma (NHL).
loading...
    loading...
Cat. No.: HY-P991514

Target:  

CD20

Research Areas:  

Cancer

MIL62 is an anti-CD20 monoclonal antibody. MIL62 shows enhanced affinity for the FcγRⅢa receptors and direct B-cell killing effects. MIL62 has antibody-dependent cell-mediated cytotoxicity (ADCC) activity. MIL62 can be used for the study of non-Hodgkin lymphoma (NHL) .
loading...
    loading...
Cat. No.: HY-P99660
CAS No.: 2573121-53-4
Synonyms: IGM-2323

Target:  

CD20 CD3

Research Areas:  

Inflammation/Immunology Cancer

Imvotamab (IGM-2323) is a CD20 and CD3 bispecific IGM antibody with dual action mechanism. Imvotamab is used to induce physiological T cell activation to prevent over-stimulation and subsequent down-regulation of immune function. Imvotamab can be used for the study of B-cell malignant tumors, multiple myeloma (MM) and non-Hodgkin's lymphoma (NHL) .
loading...
    loading...
Cat. No.: HY-174396
CAS No.: 3075011-99-0
PI3Kδ/HDAC6-IN-1 (Compound 22E) is an orally active and dual inhibitor of PI3Kδ and HDAC6 with IC50 values of 2.4 nM and 6.2 nM, respectively. PI3Kδ/HDAC6-IN-1 exhibits potent antiproliferative effects on non-Hodgkin lymphoma (NHL) cells and possesses in vivo antitumor activity without significant toxicity. PI3Kδ/HDAC6-IN-1 arrests the cell cycle at the G0/G1 phase and induces apoptosis. PI3Kδ/HDAC6-IN-1 blocks the PI3K/AKT/mTOR signaling pathway and increases the acetylation levels of α-tubulin and histone H3 .
loading...
    loading...
Cat. No.: HY-RS12317
Research Areas:  

Others

RTEL1 Human Pre-designed siRNA Set A contains three designed siRNAs for RTEL1 gene (Human), as well as a negative control, a positive control, and a FAM-labeled negative control.

loading...
    loading...
Cat. No.: HY-147792
CAS No.: 2650546-39-5
Target:  

PI3K Apoptosis

Research Areas:  

Cancer

WNY1613 is a potent and selective PI3Kδ inhibitor with piperazinone-containing purine scaffold. WNY1613 induces cancer cell apoptosis and inhibits the phosphorylation of PI3K downstream components in NHL cell lines. WNY1613 exhibits anti-NHL activity in vitro and in vivo .
loading...
    loading...
Cat. No.: HY-P991545

Target:  

CD20

Research Areas:  

Cancer

BVX20 is a human monoclonal antibody that binds to CD20. BVX20 can kill B-cells through recruiting the immune system. BVX20 can be studied in research for relapsed or chemotherapy-resistant follicular B-cell NHL and CD20-positive diffuse large B-cell NHL .
loading...
    loading...